- Record: found
- Abstract: found
- Article: not found
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S Heier
1 ,
David M Brown ,
Victor Chong ,
Jean-Francois Korobelnik ,
Peter K Kaiser ,
Quan Dong Nguyen ,
Bernd Kirchhof ,
Allen Ho ,
Yuichiro Ogura ,
George D Yancopoulos ,
Neil Stahl ,
Robert Vitti ,
Alyson J Berliner ,
Yuhwen Soo ,
Majid Anderesi ,
Georg Groetzbach ,
Bernd Sommerauer ,
Rupert Sandbrink ,
Christian Simader ,
Ursula Schmidt-Erfurth
Dec 2012
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Two similarly designed, phase-3 studies (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD [VIEW 1, VIEW 2]) of neovascular age-related macular degeneration (AMD) compared monthly and every-2-month dosing of intravitreal aflibercept injection (VEGF Trap-Eye; Regeneron, Tarrytown, NY, and Bayer HealthCare, Berlin, Germany) with monthly ranibizumab.